Amanta Healthcare Limited — Q4 FY26 earnings call

Call held 21 May 2026

Management summary

Amanta Healthcare delivered a strong Q4 and FY26 performance, with full-year revenue of INR 288 crores and PAT growing over 42% to INR 15 crores, supported by robust operating leverage and reduced finance costs. The company significantly deleveraged its balance sheet, improving its debt-to-equity ratio from 3x to nearly 1x. Strategic initiatives include expanding SteriPort capacity and commissioning a captive solar power project, despite challenges from rising raw material costs.

Highlights

  • Full year FY26 Revenue reached INR 288 crores, reflecting resilience and consistent operating model.

  • Full year FY26 PAT grew significantly by over 42% year-on-year to INR 15 crores, driven by operating leverage and reduced finance costs.

  • EBITDA margin remained stable at 22% for FY26, indicating effective cost control and improved absorption of fixed overheads.

  • Debt-to-equity ratio improved from 3x to nearly 1x, strengthening the balance sheet.

  • The 10.8 MW captive solar power project is expected to save INR 75 lakh per month from Q1 FY27, enhancing energy efficiency and ESG profile.

Concerns

  • Raw material (polymer) prices have increased by roughly 60-70%, though the company has revised prices and expects to remain neutral.

  • An initial pile-up of finished goods inventory is expected for 3-4 months post SteriPort capacity expansion before reaching equilibrium.

Key financials

2 periods

Q4 FY26

  • Revenue
    ₹77 Cr
    YoY +6.8%
  • Net Profit
    ₹5.5 Cr
    YoY +28%
  • PAT Margin
    7%

FY26

  • Revenue
    ₹288 Cr
    YoY +5%
  • EBITDA
    ₹63 Cr
  • EBITDA Margin
    22%
  • PAT
    ₹15 Cr
    YoY +42%
  • PAT Margin
    5%

What they filed

Q1 FY27: revenue up 5.3%, net profit down 5.7% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue67 68 72 65 71 +6%74 +10%77 +7%69 +5%
EBITDA14 15 19 15 15 +6%15 +2%15 −21%15 −2%
Net profit2 4 6 4 1 −46%5 +8%6 −7%3 −6%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Capital allocation

high confidence
  • Capex Capex disclosed
    • SteriPort capacity expansion from 6.6 crore bottles to 12 crore bottles per year
    • 10.8 megawatt captive solar power project
    With utilization levels remaining healthy, we are now expanding capacity from 6.6 crore bottles per year to roughly 12 crore bottles per year. This is mainly to capture the growing market, I would say sub-market of IV fluid, which is two-port system. These kind of closed container systems are preferred in therapies like oncology, critical care, pediatricians and anesthesists. The upcoming expansion is expected to meaningfully improve scale and operating leverage over coming years. Our 10.8 megawatt captive solar power project, which is under implementation, is expected to reduce power cost meaningfully from year '27 onwards while also strengthening our ESG profile. This project is about to get commissioned in five days to six days.
  • Debt 1.0× EBITDA
    • Repayment Replaced debt with cheaper debt, 90% borrowing in single-digit
    • Repayment Expect to replace around INR30 crores to INR40 crores of debt with lower interest rate in next six months ₹30 Cr
    • Repayment Reduced debt from INR 234 crores (March '26) to INR 204 crores (as of call date) by repaying Bajaj Finance debt in early April. ₹30 Cr
    Over the last three years, we have significantly reduced leverage with our debt-to-equity ratio improving from 3x to nearly 1x today.

Guidance & targets

Capacity

  • SteriPort annual bottle capacity Capacity · upcoming expansion · High confidence 12 crore bottles

    Previously 6.6 crore bottles → 12 crore bottles

    With utilization levels remaining healthy, we are now expanding capacity from 6.6 crore bottles per year to roughly 12 crore bottles per year.

    — Bhavesh Patel

Operational Efficiency

  • Solar power project commissioning Operational Efficiency · upcoming · High confidence 5-6 days
    This project is about to get commissioned in five days to six days.

    — Bhavesh Patel

Cost Savings

  • Solar power project monthly savings Cost Savings · from year '27 onwards · High confidence INR 75 lakh
    Our 10.8 megawatt captive solar power project, which is under implementation, is expected to reduce power cost meaningfully from year '27 onwards while also strengthening our ESG profile. This project is about to get commissioned in five days to six days. So at the moment there are two initiatives. One is solar, which is a substantial, I mean, cost-saving initiative. So that I think will save roughly INR75 lakh a month. So we got the connections done last week and we are expecting meters to get installed in next five days also. So by 25th May or maybe 30th May, we should start accruing the benefit of that at the rate of INR75 lakh a month.

    — Bhavesh Patel

Market Growth

  • IV fluid consumption growth (India) Market Growth · year-on-year · High confidence 8-10%
    So IV fluid consumption in India is growing at roughly 8% to 10% year-on-year.

    — Bhavesh Patel

  • Incremental IV fluid demand (India) Market Growth · every year · High confidence 12-15 crore bottles
    So every year you have incremental demand of 12 crore to 15 crore bottles.

    — Bhavesh Patel

  • Two-port system growth Market Growth · ongoing · High confidence 12-13%
    And I would say the two-port system, if the IV fluid demand is growing at around say 8%, the two-port system will grow at 12% to 13% because there is conversion happening from conventional pack to two-port system.

    — Bhavesh Patel

Market Share

  • SteriPort market share Market Share · by 2030 · High confidence 20-25%
    By 2030, this demand should grow to roughly 75 crore bottles to 80 crore bottles. And we envisage to have around 20% to 25% market share because targeting higher market share in generic space doesn't make sense.

    — Bhavesh Patel

Operational Readiness

  • SteriPort Line 3 operational date Operational Readiness · Q1 FY27 · High confidence June 20, 2026
    So by 20th June we should be able to get operational.

    — Bhavesh Patel

Revenue

  • SteriPort additional revenue (Year 1) Revenue · FY27 · High confidence INR 80-85 crores
    Yes, yes, absolutely. So our endeavor would be to get operational by 20th June, because the machine trials have been completed last week and all other systems are being -- they've already been integrated. Now the mopping up operation of cleaning and validation etcetera, is going on and we are keeping margin of around 10 days in that also. So what looks to be a final date on paper like 10th May, we are assuming that 10 days buffer would be wiser. So from 20th June we are hoping to be operational. So we should get three full quarters. Got it. So roughly INR80 crores to INR85 crores from SteriPort in year one and the full impact of the INR110 crores, 120 crores will be visible in year two.

    — Bhavesh Patel

  • SteriPort additional revenue (Year 2) Revenue · FY28 · High confidence INR 110-120 crores
    Got it. So roughly INR80 crores to INR85 crores from SteriPort in year one and the full impact of the INR110 crores, 120 crores will be visible in year two.

    — Bhavesh Patel

Profitability

  • SteriPort EBITDA margin Profitability · ongoing · High confidence 26-27%
    Right, right, right. Perfect, perfect. Got it. And the EBITDA margins for SteriPort, is safe to assume 26%-27% just for SteriPort? Yes.

    — Bhavesh Patel

  • Overall EBITDA margin Profitability · going forward · High confidence 24-25%

    Previously 22% → 24-25%

    Yes. So in current portfolio, existing portfolio, on a overall basis, all product mix at company level, we are at 22% margin currently 22% EBITDA margin, which you can see from the results. The new product line is expected to have about 27% EBITDA margin only for SteriPort. So combining the new and the existing, on an average basis we will be expecting between 24% to 25% EBITDA margin going forward.

    — Paras Mehta

  • Overall PAT margin Profitability · short-term · High confidence 5-6%
    Yes. So this 5% is sustainable, 5% to 6% is sustainable in the short-term till we leverage it fully.

    — Paras Mehta

  • Overall PAT margin improvement Profitability · once fully leveraged in current year · High confidence at least 3%
    Once we leverage in the current year then going forward, it will be improving by at least 3%.

    — Paras Mehta

Capacity Utilization

  • SteriPort additional capacity utilization Capacity Utilization · from day one · High confidence 95-100%
    Yes. So, we are our capacity calculation is such that we normally in BFS, we assume 24 hours of operating hours. In SteriPort ISBM, because of the process characteristic, we assume 20 hours of operational hours -- operating hours. So, there is enough buffer for that and we will be running at 95% to 100% capacity from day one.

    — Bhavesh Patel

Product Pipeline

  • Number of products in pipeline (ophthalmic/inhalation) Product Pipeline · ongoing · High confidence 20 products
    So right now, we have 20 products in pipeline in these two categories.

    — Bhavesh Patel

Working Capital

  • Working capital cycle Working Capital · near future · High confidence 110 days

    Previously 120-125 days → 110 days

    So our current working capital cycle is about 100-plus days. To be precise, it will be ranging between 120 to 125 days and we expect it to go about 110 days in near future.

    — Paras Mehta

Export Share

  • Export revenue as % of total revenue Export Share · FY26 · High confidence 39%
    So, in year '25-'26, our total export was around 39% of the revenue.

    — Bhavesh Patel

What to watch in Q1 FY27

SteriPort Line 3 Commercial Operations

next quarter (Q1 FY27)
Current Equipment installed, commissioning completed, minor fine-tuning
Target Operational by June 20, 2026

Why it matters

This is a major capacity expansion expected to drive significant revenue and margin growth from FY27.

So by 20th June we should be able to get operational.

Risks & concerns

  • Raw material price volatility (polymer)

    medium

    Polymer prices have increased by 60-70%, impacting costs, but company has revised prices and expects to remain neutral.

    The plastic prices have gone up and this is impacting almost every aspect of our life, right from FMCG products to pharmaceutical. Our objective in such situation is first to secure the supplies... the polymer prices have gone up by roughly 60% to 70%. We have already revised our prices and we don't envisage any resistance.

    Analyst acknowledged

  • Initial inventory build-up post SteriPort expansion

    low

    Some finished goods inventory pile-up is expected for 3-4 months after the new SteriPort line becomes operational, before sales catch up.

    So, in first quarter there could be some ramp up of finished goods. In three to four months, we will reach the equilibrium where what you produce is sold, and thereafter there is reduction in the inventory level. So, this typically 9 months to 10 months cycle.

    Management acknowledged

Q&A highlights

8 direct
Raw material price increase and impact on gross margins Direct
The plastic prices have gone up and this is impacting almost every aspect of our life, right from FMCG products to pharmaceutical. Our objective in such situation is first to secure the supplies... The good part for us is that the material that we use comes from Far East, mainly, South Korea... the polymer prices have gone up by roughly 60% to 70%. We have already revised our prices and we don't envisage any resistance. The total impact could be around INR2 per bottle in SteriPort.

Addresses the significant increase in raw material costs and management's strategy to mitigate margin impact through price revisions.

Asked by Akash Jain

SteriPort price sensitivity and potential downgrading by customers Direct
INR2 increase in price will not move the needle much in my opinion and we have not encountered any resistance so far... We initiated a price revision I think 20, 25 days back and there is no resistance so far.

Clarifies that despite raw material price hikes, the premium SteriPort product is not facing resistance or downgrading from customers due to its value proposition.

Asked by Akash Jain

SteriPort expansion status and commercial readiness Direct
Coming to SteriPort, all the equipments have been installed and stage-wise commissioning has been completed. The engineers from Italy, they were at the site for more than a month. We have taken the trials. Some minor fine-tuning is being done. The utilities have been commissioned... So by 20th June we should be able to get operational.

Provides a clear timeline and status update on the critical SteriPort capacity expansion, indicating commercial operations are imminent.

Asked by Akash Jain

Debt refinancing, cost of debt, and future finance costs Direct
The finance cost has come down for two reasons. One is we have normal repayment and secondly, we have replaced the debt with a cheaper debt. So I think today I don't think we have I think 90% borrowing is in single-digit... the debt of INR234 crore total debt, but as on today while we are talking, it is INR204 crore.

Explains the significant reduction in finance costs and current debt levels, highlighting balance sheet strength and future plans for further debt optimization.

Asked by Aniket Nikumb

Competition and market share strategy for two-port systems Direct
So when we launched SteriPort, we were the segment creators and then so at that stage you have 100% market share which eventually came down to 50%. What we believe is that right now the total demand of SteriPort is around 20 crore bottles, 25 crore bottles, which is growing faster than the average growth rate of IV fluid. By 2030, this demand should grow to roughly 75 crore bottles to 80 crore bottles. And we envisage to have around 20% to 25% market share because targeting higher market share in generic space doesn't make sense.

Outlines the company's strategic approach to market share in the two-port system, emphasizing sustainable growth over aggressive, uneconomical market capture.

Asked by Rishabh Shah

Initiatives to drive adoption of two-port systems Direct
we had extensive campaign right from beginning. For instance, we worked on two fronts. One is we worked together with a university, their pharmaceutical and engineering department, and we had very extensive protocol for testing the product right from its transparency to the impact it can take, to the strength, tensile strength, conductivity, how the container behaves under impact... In Stage 2, we had stability not stability, compatibility trials of most commonly used onco drugs...

Details the company's efforts to educate the market and healthcare professionals about the benefits and superior attributes of SteriPort, supporting its value proposition.

Asked by Aniket Nikumb

NPPA classification and pricing for two-port systems (SteriPort vs. Eurohead) Direct
No. There is no difference. Same pricing, because both are having two-port system with collapsibility. So they have to develop that they have to demonstrate that their container are collapsible, that's all. If they are fully collapsible, then they will also be able to claim the same price. But many companies who have Eurohead kind of offering, they have failed to get this NPPA classification, because they can't demonstrate -- they fail to demonstrate their collapsibility.

Clarifies the competitive advantage of SteriPort in meeting regulatory standards for collapsibility, which allows it to command similar pricing to other compliant two-port systems while competitors struggle.

Asked by Saket Saurabh

Working capital cycle and expected improvement Direct
So our current working capital cycle is about 100-plus days. To be precise, it will be ranging between 120 to 125 days and we expect it to go about 110 days in near future.

Provides insight into the company's working capital management and its target for efficiency improvement in the near future.

Asked by Nupur

3 min read 7 chapters

Detailed narrative

Strong Financial Performance and Margin Expansion in FY26

Amanta Healthcare reported a robust financial performance for FY26, with revenue reaching INR 288 crores, marking a 5% year-on-year growth. Profitability saw significant improvement, with PAT growing over 42% year-on-year to INR 15 crores. The company maintained a stable EBITDA margin of 22% for the full year, and PAT margin expanded by 100 basis points to 5%, reflecting effective cost control and operating leverage.

Strategic Capacity Expansion and Operational Readiness

The company is expanding its SteriPort capacity from 6.6 crore bottles to 12 crore bottles per year, with the new line expected to be operational by June 20, 2026. This expansion is crucial for capturing the growing IV fluid market, particularly the two-port system segment. Additionally, a 10.8 MW captive solar power project is nearing commissioning (expected by May 30, 2026), which is projected to save INR 75 lakh per month from Q1 FY27, enhancing energy efficiency and reducing operational costs.

Significant Balance Sheet Deleveraging

Amanta Healthcare has made substantial progress in strengthening its balance sheet, reducing its debt-to-equity ratio from 3x to nearly 1x over the last three years. The company has replaced expensive debt with cheaper alternatives, resulting in approximately 90% of its borrowing now being in single-digit interest rates. The total debt as of March '26 was INR 234 crores, which has further reduced to INR 204 crores by the call date due to early April repayments.

Product Portfolio and Market Traction

The SteriPort platform continues to be a key growth driver, contributing nearly 42% of the revenue. Built on advanced ISBM technology, SteriPort offers superior sterilization and lower contamination risk. The company is also strengthening its Small Volume Parenterals (SVP) portfolio, focusing on high-value segments like inhalation solutions and preservative-free ophthalmics, which contribute nearly 20% of SVP revenue.

Raw Material Price Management and Pricing Strategy

The company acknowledged a significant increase of 60-70% in polymer raw material prices. However, management stated that they have revised their product prices, including an approximate INR 2 per bottle increase for SteriPort, and have not encountered resistance from the market. This proactive pricing strategy aims to maintain gross margins and ensure neutrality against rising input costs.

Market Outlook and Growth Drivers

The Indian IV fluid consumption market is growing at 8-10% year-on-year, with an incremental demand of 12-15 crore bottles annually. The two-port system segment is growing even faster at 12-13% due to conversion from conventional packs. Amanta aims for a 20-25% market share in the two-port system by 2030, focusing on specialized and differentiated products rather than aggressive generic market share.

Operational Efficiencies and Future Growth Priorities

Beyond the solar project, the company is implementing various initiatives to improve operational efficiencies. Key priorities for FY27 include enhancing regulatory approvals, developing a product pipeline (currently 20 products in pipeline), expanding export opportunities in both advanced and semi-regulated markets, and maintaining financial prudence while executing growth capex. The working capital cycle is targeted to improve from 120-125 days to 110 days in the near future.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls